Ht-Logo-gigapixel-icon
Monday, March 27, 2023
Canada’s Politics and Government News Source Since 1989
Monday, March 27, 2023 | Latest Paper

Michael May

Michael May, PhD, is president and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies, launches new companies and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. 

Time to go on offence with Canada’s bio-manufacturing strategy

Opinion | BY MICHAEL MAY | September 13, 2021
Stainless steel bioreactors, pictured. It is encouraging and exciting that bio-manufacturing has become a priority of the Canadian life sciences enterprise, and it is understandable that recent investments have been driven by COVID-19 vaccine development and manufacturing, writes Michael May. Photograph courtesy of Commons Wikimedia/Rick Lawless
Opinion | BY MICHAEL MAY | September 13, 2021
Opinion | BY MICHAEL MAY | September 13, 2021
Stainless steel bioreactors, pictured. It is encouraging and exciting that bio-manufacturing has become a priority of the Canadian life sciences enterprise, and it is understandable that recent investments have been driven by COVID-19 vaccine development and manufacturing, writes Michael May. Photograph courtesy of Commons Wikimedia/Rick Lawless